STAAR Surgical Company appointed David Bailey as Chief Commercial Officer, effective September 8, 2026. Mr. Bailey returns to the company he previously led as CEO from 2001 to 2008 and President of International Operations until 2011. His compensation includes an annual base salary of approximately $575,000, a target bonus of 60% of base, and equity grants valued at $850,000 in RSUs plus a $1,400,000 long-term incentive award split between options and RSUs. The appointment aims to accelerate revenue growth for the EVO ICL product line as laser refractive procedures decline globally. STAAR Surgical Company is a medical device manufacturer specializing in implantable phakic intraocular lenses for vision correction.

STAAR Surgical Company reported second quarter 2026 financial results for the period ended July 3, 2026. Net sales reached $93.5 million, an 111% increase year-over-year from $44.3 million, driven by over 100% growth in China and double-digit gains in the Americas. The company posted net income of $8.1 million, or $0.16 per diluted share, compared to a net loss of $(16.8) million in the prior year period. Adjusted EBITDA improved to $20.0 million from a loss of $(14.8) million. Gross margin expanded to 74.5% from 74.0%. Cash and investments totaled $181.5 million, with no outstanding debt. Warren Foust assumed the role of President and Chief Executive Officer, succeeding Deborah Andrews who continues as CFO. STAAR Surgical Company operates in the medical device industry, specializing in implantable phakic intraocular lenses for vision correction.

STAAR Surgical Company appointed Warren Foust as President and Chief Executive Officer, effective August 4, 2026, adding him to the Board of Directors. Mr. Foust receives a $730,000 annual base salary and significant equity grants including RSUs and performance-based stock options with hurdles at $50, $75, and $100 per share. Deborah Andrews transitions from Interim Co-CEO to Executive Vice President while retaining her role as Chief Financial Officer. This leadership change follows an extensive global search aimed at driving revenue growth and innovation in the ophthalmic surgery industry.

At its 2026 Annual Meeting of Shareholders held on June 18, 2026, STAAR Surgical Company shareholders approved Amendment No. 2 to the Amended and Restated Omnibus Equity Incentive Plan, increasing the number of common shares reserved for issuance by 3.9 million shares. Shareholders also elected seven directors, ratified BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending January 1, 2027, and approved executive compensation on an advisory basis. The company operates in the medical device industry, specializing in implantable lenses for vision correction.

On June 8, 2026, STAAR Surgical Company's Compensation Committee approved an increase to the annual base salary of Interim Co-CEO and CFO Deborah Andrews to $575,000, up from $512,000. The Committee also increased her target annual cash bonus from 55% to 60% of her base salary, effective immediately. STAAR Surgical Company is a medical device company that manufactures and sells intraocular lenses.